Gritstone Oncology, Inc. (GRTS): Price and Financial Metrics

Gritstone Oncology, Inc. (GRTS)

Today's Latest Price: $18.42 USD

1.12 (6.47%)

Updated Jan 28 11:16am

Add GRTS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 488 in Biotech

See all "A" rated Strong Buy stocks

GRTS Stock Summary

  • GRTS's went public 2.34 years ago, making it older than just 5.3% of listed US stocks we're tracking.
  • GRTS's price/sales ratio is 182.85; that's higher than the P/S ratio of 97.5% of US stocks.
  • The volatility of Gritstone Oncology Inc's share price is greater than that of 97.74% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Gritstone Oncology Inc, a group of peers worth examining would be VBLT, SYBX, ORMP, ARCT, and EVGN.
  • Visit GRTS's SEC page to see the company's official filings. To visit the company's web site, go to

GRTS Stock Price Chart Interactive Chart >

Price chart for GRTS

GRTS Price/Volume Stats

Current price $18.42 52-week high $35.20
Prev. close $17.30 52-week low $2.54
Day low $17.53 Volume 795,660
Day high $20.08 Avg. volume 8,841,245
50-day MA $6.76 Dividend yield N/A
200-day MA $5.16 Market Cap 695.61M

Gritstone Oncology, Inc. (GRTS) Company Bio

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing personalized cancer immunotherapies for various cancer types in the United States. It is developing GRANITE-001, a personalized immunotherapy product for cancer patients; and SLATE-001 for patients with common tumor neoantigens. The company was founded in 2015 and is based in Emeryville, California.

GRTS Latest News Stream

Event/Time News Detail
Loading, please wait...

GRTS Latest Social Stream

Loading social stream, please wait...

View Full GRTS Social Stream

Latest GRTS News From Around the Web

Below are the latest news stories about Gritstone Oncology Inc that investors may wish to consider to help them evaluate GRTS as an investment opportunity.

Is This Under-the-Radar COVID Stock the Next Moderna?

Gritstone Oncology (NASDAQ: GRTS) started the week as a little-known player in the coronavirus vaccine space. Its shares -- and market capitalization -- soared. Gritstone said its vaccine candidate targets that very problem.

Yahoo | January 23, 2021

Gritstone’s Unique Approach Can Set Its 2nd Gen COVID-19 Vaccine Apart, Says Analyst

Think coronavirus stocks are so 2020? Think again. Shares of Gritstone Oncology (GRTS) took off by a whooping 302% over the past two trading sessions, after the company disclosed promising news concerning the development of its second-generation coronavirus vaccine. The company has entered an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to initiate a phase 1 trial which focuses on Gritstone’s heterologous prime-boost strategyfor vaccination and makes use of the company’s EDGE algorithm for T-cell epitope selection. Phase 1 is anticipated to kick off in 1H21, and should it prove successful, a Phase 2 study will follow in 2H21.

Marty Shtrubel on TipRanks | January 21, 2021

Gritstone Oncology downgraded by Baird on ‘COVID-19 vaccine Hype’

With the price target unchanged at $8 per share, Baird lowers its recommendation on Gritstone Oncology (GRTS) to Underperform from Outperform, citing a ‘recent substantial upside’ in the stock despite ‘a myriad issues’ that the company’s COVID-19 vaccine development likely to encounter.After a five-day losing streak, the shares have added ~13.7% so...

Seeking Alpha | January 20, 2021

Gritstone Oncology (GRTS) Investor Presentation - Slideshow

The following slide deck was published by Gritstone Oncology, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 19, 2021

Gritstone Soars Due to Progress on COVID Vaccine

Gritstone entered into a clinical trial agreement with the National Institute of Allergy and Infectious Diseases.

Yahoo | January 19, 2021

Read More 'GRTS' Stories Here

GRTS Price Returns

1-mo 383.46%
3-mo 574.73%
6-mo 474.73%
1-year 94.51%
3-year N/A
5-year N/A
YTD 367.51%
2020 -56.08%
2019 -41.94%
2018 N/A
2017 N/A
2016 N/A

Continue Researching GRTS

Here are a few links from around the web to help you further your research on Gritstone Oncology Inc's stock as an investment opportunity:

Gritstone Oncology Inc (GRTS) Stock Price | Nasdaq
Gritstone Oncology Inc (GRTS) Stock Quote, History and News - Yahoo Finance
Gritstone Oncology Inc (GRTS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8805 seconds.